Sellas Life Sciences is trading now at $11.05, down 5.23%, amid continued investor concern surrounding its Phase 3 REGAL trial and the timing of topline results.
- Pomerantz said the trial reportedly reached its 80th patient-death event, expected to trigger results disclosure, but results remained unavailable.
- No new September 17 company announcement was found; broader markets were higher, making a company-specific explanation more likely.